about
Protein Kinase C δ: a Gatekeeper of Immune HomeostasisThe biological significance of evolution in autoimmune phenomenaRegulatory T-Cell (Treg) hybridoma as a novel tool to study Foxp3 regulation and Treg fateHyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients.Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentLupus: an overview of the disease and management options.Biologic therapy for autoimmune diseases: an update.To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice.The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosusThe Diagnosis and Treatment of Systemic Lupus ErythematosusDisseminated granuloma annulare: a cutaneous adverse effect of anti-tnf agentsGender differences in autoimmunity associated with exposure to environmental factorsAutoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritisSpecific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies.Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus().Potential role of statins on wound healing: review of the literature.Environment and lupus-related diseases.The therapeutic potential of epigenetics in autoimmune diseases.Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment.Is there a cure for systemic lupus erythematosus?TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases.Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced.Biologics in dermatology: adverse effects.A patient on RIPE therapy presenting with recurrent isoniazid-associated pleural effusions: a case report.The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies.Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-α antagonists and rituximab therapy?TNF-alpha antagonist induced lupus on three different agents.Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.The Cutaneous Spectrum of Lupus Erythematosus.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.17β-oestradiol enhances global DNA hypomethylation in CD4-positive T cells from female patients with lupus, through overexpression of oestrogen receptor-α-mediated downregulation of DNMT1.Stevens-Johnsons syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature.Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
P2860
Q27686992-EE6A4C38-15D5-404A-9537-E6D188D72E47Q28730944-1E24560E-FD36-4D32-80EE-264ACD50C722Q30425184-8D673B2F-BA0C-441E-AF37-F6B35D716C72Q33394453-51E1CF3F-0C22-4D86-838C-1189029A9223Q33428730-C2EC9D56-2617-4703-BD47-9155115743EEQ34073191-71298325-164C-49C2-ACC9-13F4B2119FC8Q34638296-5E699CC2-A872-49C9-934E-9985D660890FQ34655597-8305EC4B-66F4-4E6F-8BEA-D755408DC9E5Q35214196-ECFB7266-05BD-48FA-9F3A-521B67F9D1B4Q35294438-6F91F2DE-D9B8-4A81-A02F-03BF19A94C7EQ35692998-49E69401-49F3-4473-8A98-51EC3AEFAA8BQ35749087-EF0A9178-E0C6-4474-A6C9-03CC4210AFD5Q35827986-59F4D823-EC4F-44D4-BCAC-3F8196F32F1EQ36048476-3777EABB-BE0B-49F7-A23C-ADEDDA42965BQ36084984-4B941BC1-AB91-42DE-B4CE-E31FA7C456E6Q36418745-E03AB268-69AC-414A-B680-FE012A3A5818Q37952338-5B27DB2E-C711-4B1D-A106-24A61F429588Q37953846-BF600242-B336-42CE-A53D-95C01513B431Q37967566-3C707255-612F-4552-84BD-8482F324570EQ37977481-9E5ADA0A-AC6B-456A-9800-5201C36AAFC9Q38095888-CEB5E0FE-4F12-4725-B4D0-280D08A4DB04Q38125529-4CCA79AC-F399-4759-AB23-7048A6101EDDQ38166204-B51F6D7E-08B6-43C5-8F8D-5A72FFCF4C04Q38190033-FCBBEF41-CCC1-40FE-AA9C-62E1B6064F3CQ41120913-C79414B8-8D40-4494-8D4A-9A03D2D6BC9EQ41776999-9DA38337-383F-4E80-AF39-B01177338C55Q44803722-DDCA8A91-D495-43BC-BE53-129ADBD8DE98Q46252749-E76A93EC-F43C-419F-A477-076DB4F8BCE7Q47964826-7F93DD5E-053F-49C9-B1D1-D83C3DE539D0Q48140916-E095C88B-BDEA-4FD0-9CEE-B469C297ACA7Q48332079-7269A717-FBAA-4729-BB2B-DA2F53316735Q50083992-A0753305-B112-4D27-BA86-3109B6D0D320Q51140357-A071D443-1288-4D17-B79F-69CF0574336BQ55256134-17C962C5-6CB2-4CE0-B454-6588D204435FQ58698067-FD56AEB8-AB1F-45FF-BACE-D2C5D65E8C76
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug-induced lupus: an update.
@ast
Drug-induced lupus: an update.
@en
Drug-induced lupus: an update.
@nl
type
label
Drug-induced lupus: an update.
@ast
Drug-induced lupus: an update.
@en
Drug-induced lupus: an update.
@nl
prefLabel
Drug-induced lupus: an update.
@ast
Drug-induced lupus: an update.
@en
Drug-induced lupus: an update.
@nl
P1433
P1476
Drug-induced lupus: an update.
@en
P356
10.1016/J.AUTREV.2010.07.005
P577
2010-07-23T00:00:00Z